Mereo BioPharma Group plc (MREO) is a clinical-stage biopharmaceutical company focused on rare diseases, traded as an American Depositary Receipt (ADR) on Nasdaq. The shares were hit hard in late December 2025 after two pivotal Phase 3 trials of its lead asset, setrusumab, missed their primary endpoints. The stock, which traded near $2.00 before the readout, has since collapsed to roughly $0.29. Against that backdrop, a central price target of $1.60 — derived from the most recent analyst targets issued after the trial failure — represents a move of about 450%, a very large step that hinges on a regulatory or partnering turnaround rather than ordinary execution.
Four analyst price targets issued after the trial failure were reviewed. Jefferies (Maury Raycroft) downgraded the stock to Hold with a $0.50 target on December 30, 2025; BTIG (Julian Harrison) cut its target to $1.00 while maintaining Buy; Leerink Partners (Joseph Schwartz) reiterated Buy with a $2.00 target; and Needham (Gil Blum) lowered its target to $3.00 on January 13, 2026, while keeping Buy. The mean of these four figures is about $1.63, rounded to a $1.60 central target, with an approximate range of $0.50 to $3.00.
For context, pre-failure targets were far higher — JPMorgan had an $8.00 Overweight target as recently as August 2025, but that figure predates the Phase 3 results and is treated as stale. The wide post-failure range reflects genuine disagreement: cautious analysts argue the missed primary endpoints sharply reduce setrusumab's commercial odds, while bullish analysts emphasize the strong BMD secondary endpoint, the FDA's stated openness to alternative fracture analyses, and the value of the company's other assets. A materially relevant downgrade and target cut by Jefferies, alongside cuts at BTIG and Needham, signal that sentiment has deteriorated even among some former bulls.
With shares near $0.29, the required upside to $1.60 is roughly 450%, which must be characterized as a very large move. A return to that level would not come from incremental news but from a re-rating event — most likely regulatory progress on setrusumab, a definitive go/no-go decision on its BLA (Biologics License Application) path, or a value-creating partnership for alvelestat. The company reported cash of roughly $41 million at the end of 2025, with guidance to fund operations into mid-2027, which reduces near-term insolvency risk but also means the business remains loss-making with limited revenue.
The ADRs trade near the low end of a 52-week range that spans roughly $0.20 to $2.37, with the collapse from above $2.00 leaving significant overhead supply. The $0.50 level (Jefferies' target) and the $1.00 level (BTIG's target) stand out as psychological and analytical milestones that would need to be cleared before a move toward $1.60 becomes plausible. The stock's current position near its lows means the trend structure remains decidedly bearish absent a fundamental catalyst.
Analyst price targets typically reflect a roughly 12-month research horizon, though the exact horizon varies by firm and is not uniformly disclosed. The items most relevant to the target are regulatory feedback on setrusumab from the FDA and MHRA, any additional data analyses from the Orbit and Cosmic studies, partnering progress for alvelestat, quarterly cash balances and runway updates, and any analyst target revisions. Earnings reports matter less for near-term revenue than for cash burn and strategic commentary.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile name like MREO, where sentiment can change quickly around clinical and regulatory news, the tool can help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual review. Traders can use these signals alongside their own research to stay responsive to fast-moving market conditions.
Can MREO reach $1.60? The target is the mean of four post-failure analyst price targets and would require a roughly 450% move from the current price near $0.29 — a very large advance that cannot be assumed. The case for it rests on the strong BMD secondary endpoint, the FDA's openness to alternative analyses, a mid-2027 cash runway, and the optionality of alvelestat. The case against it rests on the missed primary fracture endpoints, unresolved regulatory risk, potential dilution, and limited control over the setrusumab program. With targets spanning $0.50 to $3.00, analyst opinion is unusually divided, and the next regulatory and partnering milestones will determine whether the stock's re-rating can begin.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MREO has been loosely correlated with RARE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then RARE could also see price increases.
| Ticker / NAME | Correlation To MREO | 1D Price Change % | ||
|---|---|---|---|---|
| MREO | 100% | +2.92% | ||
| RARE - MREO | 58% Loosely correlated | +3.47% | ||
| TRDA - MREO | 40% Loosely correlated | +3.62% | ||
| SYRE - MREO | 38% Loosely correlated | +2.24% | ||
| XNCR - MREO | 38% Loosely correlated | +1.47% | ||
| NRIX - MREO | 38% Loosely correlated | +2.83% | ||
More | ||||